Contineum Therapeutics, Inc. Class A Common Stock
CTNM · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $330,358 | $102,807 | $180,565 | $378,769 |
| - Cash | $42,633 | $20,784 | $22,470 | $21,943 |
| + Debt | $5,493 | $5,750 | $6,002 | $6,259 |
| Enterprise Value | $293,218 | $87,773 | $164,097 | $363,085 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$81 | -$79 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$12,711 | -$15,961 | -$18,032 | -$14,490 |
| % Margin | – | – | – | – |
| Net Income | -$12,792 | -$16,040 | -$15,990 | -$14,565 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.45 | -0.62 | -0.62 | -0.65 |
| % Growth | 27.4% | 0% | 4.6% | – |
| Operating Cash Flow | -$12,197 | -$15,661 | -$14,412 | -$10,202 |
| Capital Expenditures | -$98 | -$44 | -$47 | -$166 |
| Free Cash Flow | -$12,295 | -$15,705 | -$14,459 | -$10,368 |